RU2011134652A - Синергические комбинации каротиноидов и полифенолов - Google Patents
Синергические комбинации каротиноидов и полифенолов Download PDFInfo
- Publication number
- RU2011134652A RU2011134652A RU2011134652/15A RU2011134652A RU2011134652A RU 2011134652 A RU2011134652 A RU 2011134652A RU 2011134652/15 A RU2011134652/15 A RU 2011134652/15A RU 2011134652 A RU2011134652 A RU 2011134652A RU 2011134652 A RU2011134652 A RU 2011134652A
- Authority
- RU
- Russia
- Prior art keywords
- therapeutic composition
- polyphenol
- composition according
- acid
- carnosic acid
- Prior art date
Links
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract 19
- 235000013824 polyphenols Nutrition 0.000 title claims abstract 19
- 230000002195 synergetic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 35
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract 30
- 230000001225 therapeutic effect Effects 0.000 claims abstract 29
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract 12
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 10
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract 9
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract 9
- 235000013734 beta-carotene Nutrition 0.000 claims abstract 9
- 239000011648 beta-carotene Substances 0.000 claims abstract 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract 9
- 229960002747 betacarotene Drugs 0.000 claims abstract 9
- 235000012680 lutein Nutrition 0.000 claims abstract 9
- 239000001656 lutein Substances 0.000 claims abstract 9
- 229960005375 lutein Drugs 0.000 claims abstract 9
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract 9
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract 9
- 235000012661 lycopene Nutrition 0.000 claims abstract 9
- 239000001751 lycopene Substances 0.000 claims abstract 9
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract 9
- 229960004999 lycopene Drugs 0.000 claims abstract 9
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract 9
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract 6
- 229940074391 gallic acid Drugs 0.000 claims abstract 6
- 235000004515 gallic acid Nutrition 0.000 claims abstract 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract 6
- 235000005875 quercetin Nutrition 0.000 claims abstract 6
- 229960001285 quercetin Drugs 0.000 claims abstract 6
- 235000021283 resveratrol Nutrition 0.000 claims abstract 6
- 229940016667 resveratrol Drugs 0.000 claims abstract 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 5
- -1 superoxide ions Chemical class 0.000 claims abstract 5
- PXJNUPOCGBDYJJ-UHFFFAOYSA-N Phytofluen Natural products CC(CCCC(=CC=CC(=CC=CC=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)CCC=C(C)C PXJNUPOCGBDYJJ-UHFFFAOYSA-N 0.000 claims abstract 4
- OVSVTCFNLSGAMM-UZFNGAIXSA-N di-cis-phytoene Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 claims abstract 4
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 3
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- 235000021466 carotenoid Nutrition 0.000 claims abstract 3
- 150000001747 carotenoids Chemical class 0.000 claims abstract 3
- 235000012754 curcumin Nutrition 0.000 claims abstract 3
- 239000004148 curcumin Substances 0.000 claims abstract 3
- 229940109262 curcumin Drugs 0.000 claims abstract 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract 3
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims abstract 3
- 235000002780 gingerol Nutrition 0.000 claims abstract 3
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 230000001575 pathological effect Effects 0.000 claims abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 206010034674 peritonitis Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
1. Терапевтическая композиция, которая содержит один или несколько полифенолов и два или более каротиноидов, которые выбирают из группы, состоящей из лютеина, ликопена и β-каротина.2. Терапевтическая композиция по п.1, где один или несколько полифенолов выбирают из группы, состоящей из карнозной кислоты, кверцетина, резвератрола, галловой кислоты, цикориевой кислоты, гингерола и куркумина.3. Терапевтическая композиция по п.2, где полифенолом является карнозная кислота.4. Терапевтическая композиция по п.2, где полифенолом является кверцетин.5. Терапевтическая композиция по п.2, где полифенолом является резвератрол.6. Терапевтическая композиция по п.2, где полифенолом является галловая кислота.7. Терапевтическая композиция по п.2, которая, по существу, состоит из ликопена, лютеина и карнозной кислоты.8. Терапевтическая композиция по п.2, которая, по существу, состоит из лютеина, β-каротина и карнозной кислоты.9. Терапевтическая композиция по п.2, которая, по существу, состоит из ликопена, β-каротина и карнозной кислоты.10. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитоен.11. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитофлуен.12. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитоен и фитофлуен.13. Способ ингибирования или снижения образования супероксид-ионов, NO, TNF-α и/или PGEу субъекта-млекопитающего, который содержит введение указанному субъекту терапевтической композиции по любому пп.1-12.14. Способ лечения патологических состояний, в которых супероксид-ионы, NO, TNF-α и/или PGEвыполняют �
Claims (30)
1. Терапевтическая композиция, которая содержит один или несколько полифенолов и два или более каротиноидов, которые выбирают из группы, состоящей из лютеина, ликопена и β-каротина.
2. Терапевтическая композиция по п.1, где один или несколько полифенолов выбирают из группы, состоящей из карнозной кислоты, кверцетина, резвератрола, галловой кислоты, цикориевой кислоты, гингерола и куркумина.
3. Терапевтическая композиция по п.2, где полифенолом является карнозная кислота.
4. Терапевтическая композиция по п.2, где полифенолом является кверцетин.
5. Терапевтическая композиция по п.2, где полифенолом является резвератрол.
6. Терапевтическая композиция по п.2, где полифенолом является галловая кислота.
7. Терапевтическая композиция по п.2, которая, по существу, состоит из ликопена, лютеина и карнозной кислоты.
8. Терапевтическая композиция по п.2, которая, по существу, состоит из лютеина, β-каротина и карнозной кислоты.
9. Терапевтическая композиция по п.2, которая, по существу, состоит из ликопена, β-каротина и карнозной кислоты.
10. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитоен.
11. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитофлуен.
12. Терапевтическая композиция по любому пп.7-9, где указанная композиция дополнительно содержит фитоен и фитофлуен.
13. Способ ингибирования или снижения образования супероксид-ионов, NO, TNF-α и/или PGE2 у субъекта-млекопитающего, который содержит введение указанному субъекту терапевтической композиции по любому пп.1-12.
14. Способ лечения патологических состояний, в которых супероксид-ионы, NO, TNF-α и/или PGE2 выполняют функцию модулятора или медиатора указанного состояния у субъекта-млекопитающего, нуждающегося в таком лечении, где указанный способ включает в себя введение указанному субъекту терапевтической композиции по любому пп.1-12.
15. Способ лечения по п.14, где состоянием, подлежащим лечению является воспалительное состояние.
16. Способ лечения по п.14, где состояние, подлежащее лечению, выбирают из группы, состоящей из ревматоидного артрита, синдрома расстройства дыхания взрослых (СРДВ), астмы, ринита, идиопатического фиброза легких, перитонита, сердечно-сосудистого воспаления, ишемии миокарда, нарушения реперфузии, атеросклероза, сепсиса, травмы, диабета 2-го типа, ретинопатии, псориаза, желудочно-кишечного воспаления, цирроза, перитонита и воспалительного заболевания кишечника и нейродегенеративных заболеваний, включая болезнь Альцгеймера.
17. Способ по любому пп.13-16, где субъектом-млекопитающим является человеческий субъект.
18. Способ по любому пп.13-16, где терапевтическую композицию вводят в фармацевтической лекарственной форме.
19. Способ по любому пп.13-16, где терапевтическую композицию включают в продукт питания или напиток.
20. Применение комбинации одного или нескольких полифенолов и двух или более каротиноидов, которые выбирают из группы, состоящей из лютеина, ликопена и β-каротина, в производстве лекарственного средства для лечения состояний, чувствительных к ингибированию образования супероксид-ионов, NO, TNF-α и/или PGE2.
21. Применение по п.20, где один или несколько полифенолов выбирают из группы, состоящей из карнозной кислоты, кверцетина, резвератрола, галловой кислоты, цикориевой кислоты, гингерола и куркумина.
22. Применение по п.20, где полифенолом является карнозная кислота.
23. Применение по п.20, где полифенолом является кверцетин.
24. Применение по п.20, где полифенолом является резвератрол.
25. Применение по п.20, где полифенолом является галловая кислота.
26. Применение по п.20, где состоянием является воспалительное состояние.
27. Применение по п.20, где состояние, подлежащее лечению, выбирают из группы, состоящей из ревматоидного артрита, синдрома расстройства дыхания взрослых (СРДВ), астмы, ринита, идиопатического фиброза легких, перитонита, сердечно-сосудистого воспаления, ишемии миокарда, нарушения реперфузии, атеросклероза, сепсиса, травмы, диабета 2-го типа, ретинопатии, псориаза, желудочно-кишечного воспаления, цирроза, перитонита и воспалительного заболевания кишечника и нейродегенеративных заболеваний, включая болезнь Альцгеймера.
28. Применение по п.20, где карнозную кислоту используют в сочетании с ликопеном и лютеином.
29. Применение по п.20, где карнозную кислоту используют в сочетании с ликопеном и β-каротином.
30. Применение по п.20, где карнозную кислоту используют в сочетании с лютеином и β-каротином.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14559309P | 2009-01-19 | 2009-01-19 | |
US61/145,593 | 2009-01-19 | ||
US26651709P | 2009-12-04 | 2009-12-04 | |
US61/266,517 | 2009-12-04 | ||
PCT/IL2010/000045 WO2010082205A1 (en) | 2009-01-19 | 2010-01-19 | Synergistic combinations of carotenoids and polyphenols |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011134652A true RU2011134652A (ru) | 2013-02-27 |
RU2563991C2 RU2563991C2 (ru) | 2015-09-27 |
Family
ID=42339496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011134652/15A RU2563991C2 (ru) | 2009-01-19 | 2010-01-19 | Синергические комбинации каротиноидов и полифенолов |
Country Status (11)
Country | Link |
---|---|
US (3) | US20120071550A1 (ru) |
EP (2) | EP3085365A3 (ru) |
JP (2) | JP5778584B2 (ru) |
CN (2) | CN102355894B (ru) |
AU (1) | AU2010205367B2 (ru) |
BR (1) | BRPI1005154A2 (ru) |
CA (1) | CA2749202C (ru) |
ES (1) | ES2580173T3 (ru) |
PL (1) | PL2381935T3 (ru) |
RU (1) | RU2563991C2 (ru) |
WO (1) | WO2010082205A1 (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146496A0 (en) | 2001-11-14 | 2002-07-25 | Lycored Natural Prod Ind Ltd | Carotenoid composition and method for protecting skin |
CA2749202C (en) * | 2009-01-19 | 2019-11-26 | Lycored Ltd. | The use of compositions comprising carnosic acid and two or more carotenoids in the treatment of inflammation |
SG166688A1 (en) | 2009-05-14 | 2010-12-29 | Hsiehs Biotech Singapore Pte Ltd | Lycopene and resveratrol dietary supplement |
US9107853B2 (en) | 2012-10-12 | 2015-08-18 | L'oreal S.A. | Compositions containing phenolic compounds and hydrotropes for cosmetic use |
US9018177B2 (en) | 2012-10-12 | 2015-04-28 | L'oreal S.A. | Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C |
US9023826B2 (en) | 2012-10-12 | 2015-05-05 | L'oreal S.A. | Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use |
US9072919B2 (en) | 2012-10-12 | 2015-07-07 | L'oreal S.A. | Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid |
WO2014082027A2 (en) | 2012-11-26 | 2014-05-30 | Access Business Group International Llc | Antioxidant dietary supplement and related method |
CA2898284C (en) * | 2013-01-22 | 2023-03-28 | Lycored Ltd. | Compositions comprising heat-treated clear tomato concentrate |
CN108245496B (zh) * | 2013-03-19 | 2021-07-16 | 乐康瑞德有限公司 | 虾青素抗炎增效组合 |
US9901562B2 (en) | 2013-04-04 | 2018-02-27 | Lycored Ltd. | Anti-inflammatory omega-3 synergistic combinations |
US9669242B2 (en) | 2013-07-01 | 2017-06-06 | L'oreal | Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use |
CN104543983A (zh) * | 2013-10-15 | 2015-04-29 | 泰运生技有限公司 | 保健食品组合物 |
CN104083345A (zh) * | 2014-06-13 | 2014-10-08 | 华中科技大学 | 番茄红素在制备防治老年痴呆药物中的应用 |
AU2015351930B2 (en) * | 2014-11-25 | 2021-08-12 | Lycored Ltd. | Biologically-active tomato composition having reduced amount of lycopene |
CN106998778A (zh) | 2014-11-25 | 2017-08-01 | 雅培制药有限公司 | 通过向婴儿施用包含RRR‑α‑生育酚和类胡萝卜素的组合物来改善视觉处理、视敏度或两者的方法 |
KR101632839B1 (ko) * | 2015-07-10 | 2016-06-23 | 아주대학교산학협력단 | 레스베라트톨 유도체를 유효성분으로 포함하는 간경화 또는 간섬유화 예방 또는 치료용 약학 조성물 |
EP3120842A1 (en) * | 2015-07-20 | 2017-01-25 | Opterion Health AG | Peritoneal therapeutic fluid |
CN105476982A (zh) * | 2016-02-02 | 2016-04-13 | 张干 | 没食子酸的新用途 |
CN105616439A (zh) * | 2016-03-11 | 2016-06-01 | 王巧玲 | 一种治疗酒精性心肌病的胶囊剂及其制备方法 |
CA3097521C (en) | 2017-05-15 | 2023-10-17 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
US20190070244A1 (en) * | 2017-06-30 | 2019-03-07 | The New Zealand Institute For Plant And Food Research Limited | Boysenberry compositions and methods of preparation and use thereof |
TW202406562A (zh) | 2017-08-08 | 2024-02-16 | 奧德特M 蕭 | 波森莓、蘋果及黑醋栗組成物及其製備方法與用途 |
WO2019087189A1 (en) * | 2017-11-01 | 2019-05-09 | Lycored Ltd. | A method for improving ocular blood flow |
CN107823196A (zh) * | 2017-11-24 | 2018-03-23 | 广西医科大学 | 鼠尾草酸在制备治疗类风湿性关节炎药物方面的应用 |
US11318136B2 (en) | 2018-04-13 | 2022-05-03 | Seung Hyun Yoo | Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease |
CA3136554A1 (en) * | 2018-04-19 | 2019-10-24 | Fff Bioworks Llp | Synergistic hepatoprotective composition |
AU2019309497A1 (en) * | 2018-07-23 | 2021-03-11 | Lycored Ltd. | Lycopene compositions and methods for protecting skin against ultraviolet radiation |
CN110200956B (zh) * | 2019-07-17 | 2021-07-27 | 吴广森 | 一种眼科外用药物组合物 |
CN111588716A (zh) * | 2020-06-11 | 2020-08-28 | 中国医学科学院肿瘤医院 | 一种药物组合物及其在制备治疗前列腺炎产品应用 |
JP7005043B2 (ja) * | 2020-07-08 | 2022-02-10 | 株式会社東洋新薬 | 網膜保護組成物 |
WO2022128052A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammatory conditions of human skin |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033299T2 (de) * | 1990-10-06 | 2000-01-05 | Nestle Sa | Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften |
US5837311A (en) | 1993-12-13 | 1998-11-17 | Makhteshim Chemical Works Ltd. | Industrial processing of tomatoes and product thereof |
AU2001258237B8 (en) * | 2000-05-12 | 2006-02-09 | Bengt Krister Olson | Combined cartilage and plant extract compositions |
WO2002047493A2 (en) * | 2000-12-16 | 2002-06-20 | Aventis Pharma Deutschland Gmbh | Health promoting compositions |
IL141039A (en) * | 2001-01-23 | 2006-10-31 | Lycored Natural Prod Ind Ltd | The composition for the prevention of atherosclerosis containing carotenoids and use for the preparation of drugs to inhibit LDL oxidation |
US20030008048A1 (en) * | 2001-06-08 | 2003-01-09 | David Winston | Methods and compositions for helping the body resist the effects of the aging process |
IL146449A0 (en) * | 2001-11-12 | 2002-07-25 | Lycored Natural Prod Ind Ltd | Method and pharmaceutical preparations for reducing the activity of cells |
US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
EP1470817A4 (en) * | 2002-01-31 | 2006-03-22 | Kansai Tech Licensing Org Co | COMPOSITIONS FOR PREVENTING CANCER IN HUMANS AND METHOD FOR PREVENTING CANCER IN HUMANS |
EP1476143A1 (en) * | 2002-02-15 | 2004-11-17 | DSM IP Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
JP2004035550A (ja) * | 2002-05-07 | 2004-02-05 | Access Business Group Internatl Llc | 植物栄養素栄養サプリメント |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
KR100739531B1 (ko) * | 2004-05-07 | 2007-07-13 | 주식회사 이오텍 | 리코펜과 피토에스트로겐을 포함하는 혼합 조성물 |
US9579298B2 (en) * | 2004-12-02 | 2017-02-28 | Piotr Chomczynski | Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
US20070065396A1 (en) * | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
JP2009515821A (ja) * | 2005-10-16 | 2009-04-16 | リコレッド リミテッド | 眼疾患を治療するための組成物 |
US20070141170A1 (en) * | 2005-12-20 | 2007-06-21 | Alcon Manufacturing, Ltd. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
SG10201700743PA (en) * | 2006-02-10 | 2017-03-30 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
IL173971A (en) * | 2006-02-27 | 2012-07-31 | Lycored Ltd | Compositions for treating age-related macular degeneration |
JP2007254427A (ja) * | 2006-03-24 | 2007-10-04 | Shimane Pref Gov | 抗酸化剤およびその用途 |
US8841264B2 (en) * | 2006-07-14 | 2014-09-23 | Dsm Ip Assets B.V. | Compositions |
IL184575A0 (en) * | 2007-07-12 | 2008-01-20 | Lycored Ltd | Synergistic combinations for treating hypertension |
ITMI20080003A1 (it) * | 2008-01-02 | 2009-07-03 | Alfredo Pulpito | Composizioni per uso oftalmico |
CA2749202C (en) * | 2009-01-19 | 2019-11-26 | Lycored Ltd. | The use of compositions comprising carnosic acid and two or more carotenoids in the treatment of inflammation |
-
2010
- 2010-01-19 CA CA2749202A patent/CA2749202C/en active Active
- 2010-01-19 JP JP2011545840A patent/JP5778584B2/ja not_active Expired - Fee Related
- 2010-01-19 PL PL10731120.1T patent/PL2381935T3/pl unknown
- 2010-01-19 EP EP16172113.9A patent/EP3085365A3/en not_active Withdrawn
- 2010-01-19 BR BRPI1005154A patent/BRPI1005154A2/pt not_active Application Discontinuation
- 2010-01-19 CN CN201080012356.7A patent/CN102355894B/zh active Active
- 2010-01-19 ES ES10731120.1T patent/ES2580173T3/es active Active
- 2010-01-19 WO PCT/IL2010/000045 patent/WO2010082205A1/en active Application Filing
- 2010-01-19 RU RU2011134652/15A patent/RU2563991C2/ru active
- 2010-01-19 AU AU2010205367A patent/AU2010205367B2/en active Active
- 2010-01-19 EP EP10731120.1A patent/EP2381935B1/en active Active
- 2010-01-19 CN CN201510486515.1A patent/CN105193777B/zh active Active
-
2011
- 2011-07-18 US US13/137,061 patent/US20120071550A1/en not_active Abandoned
-
2015
- 2015-05-12 JP JP2015097204A patent/JP2015205882A/ja active Pending
-
2016
- 2016-10-21 US US15/299,634 patent/US20170035713A1/en not_active Abandoned
-
2021
- 2021-11-23 US US17/533,637 patent/US20220079901A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL2381935T3 (pl) | 2016-11-30 |
JP2012515198A (ja) | 2012-07-05 |
AU2010205367A1 (en) | 2011-08-11 |
JP5778584B2 (ja) | 2015-09-16 |
CN105193777A (zh) | 2015-12-30 |
EP3085365A3 (en) | 2017-01-04 |
EP3085365A2 (en) | 2016-10-26 |
ES2580173T3 (es) | 2016-08-19 |
JP2015205882A (ja) | 2015-11-19 |
US20120071550A1 (en) | 2012-03-22 |
CN105193777B (zh) | 2019-06-28 |
BRPI1005154A2 (pt) | 2018-02-06 |
EP2381935A1 (en) | 2011-11-02 |
RU2563991C2 (ru) | 2015-09-27 |
CA2749202A1 (en) | 2010-07-22 |
CN102355894A (zh) | 2012-02-15 |
EP2381935A4 (en) | 2013-03-13 |
AU2010205367B2 (en) | 2015-06-18 |
CN102355894B (zh) | 2016-06-15 |
WO2010082205A1 (en) | 2010-07-22 |
EP2381935B1 (en) | 2016-06-01 |
US20170035713A1 (en) | 2017-02-09 |
CA2749202C (en) | 2019-11-26 |
US20220079901A1 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011134652A (ru) | Синергические комбинации каротиноидов и полифенолов | |
Liobikas et al. | Uncoupling and antioxidant effects of ursolic acid in isolated rat heart mitochondria | |
Zeni et al. | Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system | |
Kang et al. | Improvement of high-fat diet-induced obesity by a mixture of red grape extract, soy isoflavone and L-carnitine: implications in cardiovascular and non-alcoholic fatty liver diseases | |
EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
WO2010114824A8 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
IL203448A (en) | History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them | |
BRPI0610180A2 (pt) | métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação | |
WO2013183062A3 (en) | Palatable formulations of ibuprofen | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
PH12016501584B1 (en) | Composition for improving blood circulation, containing extract of lindera obtusiloba as active ingredient | |
Wan et al. | Schisandrin rescues depressive-like behaviors induced by chronic unpredictable mild stress via GDNF/ERK1/2/ROS and PI3K/AKT/NOX signaling pathways in mice | |
JP2016521289A5 (ru) | ||
Marete et al. | Feverfew as a source of bioactives for functional foods: Storage stability in model beverages | |
Högger | Nutrition-derived bioactive metabolites produced by gut microbiota and their potential impact on human health | |
RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
CN105853948A (zh) | 一种防治心脑血管栓塞的保健品 | |
WO2012019435A3 (en) | Composition for treating neurodegenerative disease or neuropathological condition | |
JP4537024B2 (ja) | 炎症疾患予防・治療剤 | |
Mahendran et al. | Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment | |
EA201592297A1 (ru) | Композиции агомелатина, содержащие агомелатин в форме сокристаллов | |
RU2015135595A (ru) | Композиции, содержащие термообработанный прозрачный томатный концентрат | |
Alipanah et al. | Effect of Viola odorata extract on cell survival of triple negative breast cancer MDA-MB-468 cells | |
CN105495177A (zh) | 一种降血脂饮料配方及其制作方法 |